Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis

Lawrence D. Jacobs, Diane L. Cookfair, Richard A. Rudick, Robert M. Herndon, John R. Richert, Andres M. Salazar, Jill S. Fischer, Donald E. Goodkin, Carl V. Granger, Jack H. Simon, John J. Alam, David M. Bartoszak, Dennis Bourdette, Jonathan Braiman, Carol M. Brownscheidle, Michael E. Coats, Stanley L. Cohan, David S. Dougherty, Revere P. Kinkel, Michele MassFrederick E. Munschauer, Roger L. Priore, Patrick M. Pullicino, Barbara J. Scherokman, Bianca Weinstock-Guttman, Ruth Whitham

Research output: Contribution to journalArticle

2223 Citations (Scopus)

Abstract

The accepted standard treatment of relapsing multiple sclerosis consists of medications for disease symptoms, including treatment for acute exacerbations. However, currently there is no therapy that alters the progression of physical disability associated with this disease. The purpose of this study was to determine whether interferon beta-1a could slow the progressive, irreversible, neurological disability of relapsing multiple sclerosis. Three hundred one patients with relapsing multiple sclerosis were randomized into a double-blinded, placebo-controlled, multicenter phase III trial of interferon beta-1a. Interferon beta-1a, 6.0 million units (30 μg), was administered by intramuscular injection weekly. The primary outcome variable was time to sustained disability progression of at least 1.0 point on the Kurtzke Expanded Disability Status Scale (EDSS). Interferon beta-1a treatment produced a significant delay in time to sustained EDSS progression (p = 0.02). The Kaplan-Meier estimate of the proportion of patients progressing by the end of 104 weeks was 34.9% in the placebo group and 21.9% in the interferon beta-1a-treated group. Patients treated with interferon beta-1a also had significantly fewer exacerbations (p = 0.03) and a significantly lower number and volume of gadolinium-enhanced brain lesions on magnetic resonance images (p-values ranging between 0.02 and 0.05). Over 2 years, the annual exacerbation rate was 0.90 in placebo-treated patients versus 0.61 in interferon beta-1a-treated patients. There were no major adverse events related to treatment. Interferon beta-1a had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium-enhanced lesions on brain magnetic resonance images. This treatment may alter the fundamental course of relapsing multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)285-294
Number of pages10
JournalAnnals of Neurology
Volume39
Issue number3
DOIs
StatePublished - 1996

Fingerprint

Multiple Sclerosis
Disease Progression
Placebos
Gadolinium
Magnetic Resonance Spectroscopy
Therapeutics
Interferon beta-1a
Intramuscular Injections
Brain
Kaplan-Meier Estimate

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., ... Whitham, R. (1996). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Annals of Neurology, 39(3), 285-294. https://doi.org/10.1002/ana.410390304

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. / Jacobs, Lawrence D.; Cookfair, Diane L.; Rudick, Richard A.; Herndon, Robert M.; Richert, John R.; Salazar, Andres M.; Fischer, Jill S.; Goodkin, Donald E.; Granger, Carl V.; Simon, Jack H.; Alam, John J.; Bartoszak, David M.; Bourdette, Dennis; Braiman, Jonathan; Brownscheidle, Carol M.; Coats, Michael E.; Cohan, Stanley L.; Dougherty, David S.; Kinkel, Revere P.; Mass, Michele; Munschauer, Frederick E.; Priore, Roger L.; Pullicino, Patrick M.; Scherokman, Barbara J.; Weinstock-Guttman, Bianca; Whitham, Ruth.

In: Annals of Neurology, Vol. 39, No. 3, 1996, p. 285-294.

Research output: Contribution to journalArticle

Jacobs, LD, Cookfair, DL, Rudick, RA, Herndon, RM, Richert, JR, Salazar, AM, Fischer, JS, Goodkin, DE, Granger, CV, Simon, JH, Alam, JJ, Bartoszak, DM, Bourdette, D, Braiman, J, Brownscheidle, CM, Coats, ME, Cohan, SL, Dougherty, DS, Kinkel, RP, Mass, M, Munschauer, FE, Priore, RL, Pullicino, PM, Scherokman, BJ, Weinstock-Guttman, B & Whitham, R 1996, 'Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis', Annals of Neurology, vol. 39, no. 3, pp. 285-294. https://doi.org/10.1002/ana.410390304
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Annals of Neurology. 1996;39(3):285-294. https://doi.org/10.1002/ana.410390304
Jacobs, Lawrence D. ; Cookfair, Diane L. ; Rudick, Richard A. ; Herndon, Robert M. ; Richert, John R. ; Salazar, Andres M. ; Fischer, Jill S. ; Goodkin, Donald E. ; Granger, Carl V. ; Simon, Jack H. ; Alam, John J. ; Bartoszak, David M. ; Bourdette, Dennis ; Braiman, Jonathan ; Brownscheidle, Carol M. ; Coats, Michael E. ; Cohan, Stanley L. ; Dougherty, David S. ; Kinkel, Revere P. ; Mass, Michele ; Munschauer, Frederick E. ; Priore, Roger L. ; Pullicino, Patrick M. ; Scherokman, Barbara J. ; Weinstock-Guttman, Bianca ; Whitham, Ruth. / Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. In: Annals of Neurology. 1996 ; Vol. 39, No. 3. pp. 285-294.
@article{b1e9a9d073a44c43b071a88ce6a74156,
title = "Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis",
abstract = "The accepted standard treatment of relapsing multiple sclerosis consists of medications for disease symptoms, including treatment for acute exacerbations. However, currently there is no therapy that alters the progression of physical disability associated with this disease. The purpose of this study was to determine whether interferon beta-1a could slow the progressive, irreversible, neurological disability of relapsing multiple sclerosis. Three hundred one patients with relapsing multiple sclerosis were randomized into a double-blinded, placebo-controlled, multicenter phase III trial of interferon beta-1a. Interferon beta-1a, 6.0 million units (30 μg), was administered by intramuscular injection weekly. The primary outcome variable was time to sustained disability progression of at least 1.0 point on the Kurtzke Expanded Disability Status Scale (EDSS). Interferon beta-1a treatment produced a significant delay in time to sustained EDSS progression (p = 0.02). The Kaplan-Meier estimate of the proportion of patients progressing by the end of 104 weeks was 34.9{\%} in the placebo group and 21.9{\%} in the interferon beta-1a-treated group. Patients treated with interferon beta-1a also had significantly fewer exacerbations (p = 0.03) and a significantly lower number and volume of gadolinium-enhanced brain lesions on magnetic resonance images (p-values ranging between 0.02 and 0.05). Over 2 years, the annual exacerbation rate was 0.90 in placebo-treated patients versus 0.61 in interferon beta-1a-treated patients. There were no major adverse events related to treatment. Interferon beta-1a had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium-enhanced lesions on brain magnetic resonance images. This treatment may alter the fundamental course of relapsing multiple sclerosis.",
author = "Jacobs, {Lawrence D.} and Cookfair, {Diane L.} and Rudick, {Richard A.} and Herndon, {Robert M.} and Richert, {John R.} and Salazar, {Andres M.} and Fischer, {Jill S.} and Goodkin, {Donald E.} and Granger, {Carl V.} and Simon, {Jack H.} and Alam, {John J.} and Bartoszak, {David M.} and Dennis Bourdette and Jonathan Braiman and Brownscheidle, {Carol M.} and Coats, {Michael E.} and Cohan, {Stanley L.} and Dougherty, {David S.} and Kinkel, {Revere P.} and Michele Mass and Munschauer, {Frederick E.} and Priore, {Roger L.} and Pullicino, {Patrick M.} and Scherokman, {Barbara J.} and Bianca Weinstock-Guttman and Ruth Whitham",
year = "1996",
doi = "10.1002/ana.410390304",
language = "English (US)",
volume = "39",
pages = "285--294",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis

AU - Jacobs, Lawrence D.

AU - Cookfair, Diane L.

AU - Rudick, Richard A.

AU - Herndon, Robert M.

AU - Richert, John R.

AU - Salazar, Andres M.

AU - Fischer, Jill S.

AU - Goodkin, Donald E.

AU - Granger, Carl V.

AU - Simon, Jack H.

AU - Alam, John J.

AU - Bartoszak, David M.

AU - Bourdette, Dennis

AU - Braiman, Jonathan

AU - Brownscheidle, Carol M.

AU - Coats, Michael E.

AU - Cohan, Stanley L.

AU - Dougherty, David S.

AU - Kinkel, Revere P.

AU - Mass, Michele

AU - Munschauer, Frederick E.

AU - Priore, Roger L.

AU - Pullicino, Patrick M.

AU - Scherokman, Barbara J.

AU - Weinstock-Guttman, Bianca

AU - Whitham, Ruth

PY - 1996

Y1 - 1996

N2 - The accepted standard treatment of relapsing multiple sclerosis consists of medications for disease symptoms, including treatment for acute exacerbations. However, currently there is no therapy that alters the progression of physical disability associated with this disease. The purpose of this study was to determine whether interferon beta-1a could slow the progressive, irreversible, neurological disability of relapsing multiple sclerosis. Three hundred one patients with relapsing multiple sclerosis were randomized into a double-blinded, placebo-controlled, multicenter phase III trial of interferon beta-1a. Interferon beta-1a, 6.0 million units (30 μg), was administered by intramuscular injection weekly. The primary outcome variable was time to sustained disability progression of at least 1.0 point on the Kurtzke Expanded Disability Status Scale (EDSS). Interferon beta-1a treatment produced a significant delay in time to sustained EDSS progression (p = 0.02). The Kaplan-Meier estimate of the proportion of patients progressing by the end of 104 weeks was 34.9% in the placebo group and 21.9% in the interferon beta-1a-treated group. Patients treated with interferon beta-1a also had significantly fewer exacerbations (p = 0.03) and a significantly lower number and volume of gadolinium-enhanced brain lesions on magnetic resonance images (p-values ranging between 0.02 and 0.05). Over 2 years, the annual exacerbation rate was 0.90 in placebo-treated patients versus 0.61 in interferon beta-1a-treated patients. There were no major adverse events related to treatment. Interferon beta-1a had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium-enhanced lesions on brain magnetic resonance images. This treatment may alter the fundamental course of relapsing multiple sclerosis.

AB - The accepted standard treatment of relapsing multiple sclerosis consists of medications for disease symptoms, including treatment for acute exacerbations. However, currently there is no therapy that alters the progression of physical disability associated with this disease. The purpose of this study was to determine whether interferon beta-1a could slow the progressive, irreversible, neurological disability of relapsing multiple sclerosis. Three hundred one patients with relapsing multiple sclerosis were randomized into a double-blinded, placebo-controlled, multicenter phase III trial of interferon beta-1a. Interferon beta-1a, 6.0 million units (30 μg), was administered by intramuscular injection weekly. The primary outcome variable was time to sustained disability progression of at least 1.0 point on the Kurtzke Expanded Disability Status Scale (EDSS). Interferon beta-1a treatment produced a significant delay in time to sustained EDSS progression (p = 0.02). The Kaplan-Meier estimate of the proportion of patients progressing by the end of 104 weeks was 34.9% in the placebo group and 21.9% in the interferon beta-1a-treated group. Patients treated with interferon beta-1a also had significantly fewer exacerbations (p = 0.03) and a significantly lower number and volume of gadolinium-enhanced brain lesions on magnetic resonance images (p-values ranging between 0.02 and 0.05). Over 2 years, the annual exacerbation rate was 0.90 in placebo-treated patients versus 0.61 in interferon beta-1a-treated patients. There were no major adverse events related to treatment. Interferon beta-1a had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium-enhanced lesions on brain magnetic resonance images. This treatment may alter the fundamental course of relapsing multiple sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=0008678962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0008678962&partnerID=8YFLogxK

U2 - 10.1002/ana.410390304

DO - 10.1002/ana.410390304

M3 - Article

C2 - 8602746

AN - SCOPUS:0008678962

VL - 39

SP - 285

EP - 294

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 3

ER -